Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?

Authors
Pae, Chi-UnHan, ChangsuBahk, Won-MyongLee, Soo-JungPatkar, Ashwin A.Masand, Prakash S.
Issue Date
8월-2021
Publisher
KOREAN COLL NEUROPSYCHOPHARMACOLOGY
Keywords
Guideline; Long-acting injectable antipsychotic; Monotherapy; Polypharmacy; Routin practice; Schizophrenia
Citation
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, v.19, no.3, pp.422 - 436
Indexed
SCIE
SCOPUS
KCI
Journal Title
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
Volume
19
Number
3
Start Page
422
End Page
436
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/136914
DOI
10.9758/cpn.2021.19.3.434
ISSN
1738-1088
Abstract
Antipsychotic monotherapy (APM) is considered best-acceptable treatment option regardless of antipsychotic class and formulation types for treating schizophrenia. However, antipsychotic polypharmacy (APP) has been also widely utilized in routine clinical practice. Despite APP has some clinical benefits it has also numerous pitfalls in relation with increased total number and doses of APs leading to adverse events as well as decrease of treatment adherence and persistence resulting in poor clinical outcomes. Recent introduction of long-acting injectable antipsychotics (LAIs) to the market has offered a chance for better medication adherence/persistence and also provided a simplification of treatment regime leading to more stabilized treatment for schizophrenia patients. When we cannot stay away from APP in the treatment of schizophrenia, clinicians need to find more proper APP regimens and thereby utilization of APP in efficient way should be a practical strategy to benefit schizophrenia patient in a real world treatment setting. With this regard, LAIs can be one of available APP regimen for treatment of schizophrenia in routine practice since their clinical utility and pharmacokinetic stability over oral APs have been well-elaborated today. However, when we have to commence LAIs as a part of APP with oral APs or other LAIs, every effort should be made before doing so whether or not validated and available treatment options or other clinical factors were not done or evaluated yet. Any treatment guidelines do not support APP regardless of the formulation of APP regimen or address two or more LAIs for treatment of schizophrenia till today.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Han, Chang su photo

Han, Chang su
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE